Clinical Trial Update: A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease [Phase 3]

View source ↗

Summary

Roche's Trontinemab is in a Phase 3 trial for early symptomatic Alzheimer's disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Trontinemab

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimers Disease | Phase 3 | Status: RECRUITING